While the introduction of BRAF inhibitors such as Vemurafenib, Dabrafenib and Encorafenib has recently revolutionized the treatment landscape of metastatic melanoma [30,31,32], the results in the treatment of CRC were largely unsatisfactory [33]. This evidence concerns the gene BRAF and colorectal carcinoma.